{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-041881","form_type":"8-K","ticker":"ENSC","cik":"0001716947","company_name":"Ensysce Biosciences, Inc.","filed_at":"2023-11-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.161265+00:00","generated_at":"2026-06-08T00:12:35.080137+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ensysce Biosciences receives Nasdaq delisting notice for non-compliance with $2.5M equity requirement","bullets":["Notified on Nov 13, 2023 of non-compliance with Nasdaq Rule 5550(b)(1) due to stockholders' equity below $2.5M as of Sept 30, 2023.","Company plans to timely request a hearing before Nasdaq Hearings Panel, staying delisting pending hearing conclusion.","No assurance the Panel will grant continued listing or that compliance can be evidenced within any extension period.","Company intends to actively explore options to regain compliance with Nasdaq listing requirements."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-041881","json":"https://secwatch.observer/filing/0001493152-23-041881.json","markdown":"https://secwatch.observer/filing/0001493152-23-041881.md","text":"https://secwatch.observer/filing/0001493152-23-041881.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716947/000149315223041881/0001493152-23-041881-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716947/000149315223041881/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T00:12:35.080137+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fb6d05be5cbbd8e94c26d87387d7a929c148cbf1","claim":"Ensysce Biosciences, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"November 13, 2023, Ensysce Biosciences, Inc. (the “Company”) received notice from the Listing Qualifications department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that, due to the Company’s non-compliance with the $2.5 million stockholders’ equity requirement set forth in Nasdaq Listing Rule 5550(b)(1) as of September 30, 2023, the Company was subject to delisting unless it timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company plans to timely request a hearing before the Panel, which request will stay any further action by Nasdaq pending the conclusion of","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1716947/000149315223041881/0001493152-23-041881-index.htm","confidence":0.95,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"5550(b)(1)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}